IMMUNOHISTOCHEMISTRY, CD 61

The IHC – CD61 (Cluster of Differentiation 61) test is an immunohistochemistry-based diagnostic assay used to detect CD61 protein expression in tissue samples. CD61, also known as Integrin Beta-3 or Platelet Glycoprotein IIIa (GPIIIa), is a cell surface protein primarily expressed on megakaryocytes and platelets.

This test is widely used in hematopathology to identify megakaryocytic cells in bone marrow and tissue specimens. CD61 staining helps pathologists diagnose and classify various hematological disorders, including megakaryocytic leukemias and myeloproliferative neoplasms. It is also useful in assessing bone marrow biopsies when evaluating platelet-producing cell populations.

Benefits of the Test

• Helps identify megakaryocytes in bone marrow tissue
• Assists in diagnosing megakaryocytic leukemia
• Supports evaluation of myeloproliferative disorders
• Improves classification of hematological malignancies
• Aids in bone marrow pathology assessment

Why Doctors Recommend This Test

Doctors recommend the IHC CD61 test when there is suspicion of bone marrow disorders or hematological malignancies involving megakaryocytes. It is commonly used in:

• Acute megakaryoblastic leukemia diagnosis
• Bone marrow biopsy evaluation
• Myeloproliferative neoplasm assessment
• Investigation of abnormal platelet production disorders
• Hematopathology studies and tumor classification

CD61 is often used alongside markers such as CD41, CD42b, CD34, MPO, and CD117 to provide a comprehensive evaluation of bone marrow and blood cell lineage disorders.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a bone marrow biopsy or tissue sample
• No fasting or medication restrictions are needed
• Previous blood counts and bone marrow findings may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected bone marrow disorders
• Individuals with abnormal platelet counts
• Cases requiring evaluation of megakaryocytic proliferation
• Patients undergoing leukemia classification studies
• Individuals with suspected myeloproliferative neoplasms

The IHC CD61 test is an important diagnostic tool in hematopathology. By identifying megakaryocyte and platelet lineage cells, it helps clinicians accurately diagnose bone marrow disorders and develop appropriate treatment strategies.